Incannex Healthcare has unveiled test results showing its hydroxychloroquine/cannabidiol drug combination (IHL-675A) was more effective as a potential treatment of chronic obstructive pulmonary disease (COPD) and asthma than CBD or hydroxychloroquine alone.
The Melbourne-based pharmaceutical development company said IHL-675A reduced inflammatory markers in mice far more than the two drugs separately.
It will now broaden claims within its initial patent filings to include using IHL-675A to treat both indications following the tests on 60 rodents.
Incannex said previous studies have demonstrated potent anti-inflammatory activity in IHL-675A, making it “an excellent candidate” for prevention and treatment of sepsis-associated acute respiratory distress syndrome (SAARDS), a leading cause of death in COVID-19 cases.
Incannex chief executive and managing director Joel Latham said: “IHL-675A is consistently showing stronger anti-inflammatory properties than CBD.
“Continued research will reveal how important this will be to the cannabinoid sector in light of continued research globally on CBD and its application to inflammatory conditions.
“The synergistic action of IHL-675A allows us to substantially expand the potential uses for IHL-675A and presents new patient treatment opportunities.”
